Truist Securities Maintains Buy on Viridian Therapeutics, Lowers Price Target to $40

Benzinga · 2d ago
Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and lowers the price target from $41 to $40.